BNBX

News

businesswire.comBNB Plus Corp. (BNBX) Secures Initial Commitments for $4.1M in Strategic Financingbusinesswire.comMay 26

businesswire.comBNB Plus Corp. Completes Historic $1.2 Million LineaDNA™ Orderbusinesswire.comApr 23

businesswire.comBNB Plus Corp. Announces Review of Strategic Alternatives to Maximize Shareholder Valuebusinesswire.comApr 20

Trade BNBX

About BNB Plus Corp.

BNB Plus Corp., established in 1983 and based in Stony Brook, NY, is a biotechnology firm dedicated to pioneering and commercializing technologies for the synthesis and identification of both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The company's operations are divided into three distinct business segments. Its Therapeutic DNA Production Services division specializes in the enzymatic manufacturing of synthetic DNA, used in the creation of nucleic acid-based treatments, and also develops and markets its proprietary RNA Polymerase (RNAP) for mRNA therapeutic production. The MDx Testing Services segment concentrates on developing clinical molecular diagnostic and genetic assessments, in addition to providing comprehensive clinical laboratory testing services. Lastly, the DNA Tagging and Security Products and Services segment leverages DNA detection techniques for securing industrial supply chains and offering various security solutions.

CEO: Clay D. Shorrock
IPO Date: Oct 8, 2025

Market Data

Open: $0.4748
High: $0.4895
Low: $0.4032
Volume: 93.5K
Avg Volume: 907.7K
52W High: $7.15
52W Low: $0.35

Valuation

Market Cap: $521k
Enterprise Value: $-428k
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-13M
Revenue: $2.1M
Net Income: $-15M
Cash: $1.7M
Debt: $193k

Events

EarningsAug 6